SCHEMBL9923795

SCHEMBL9923795

COc1cccc2oc(=O)cc(C)c12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.64
KDM4E B2RXH2 7/20 0.64
HPGD P15428 6/20 0.64
HSD17B10 Q99714 6/20 0.64
GAA P10253 2/20 0.64
LMNA P02545 2/20 0.64
TDP1 Q9NUW8 2/20 0.64
CYP2A6 P11509 1/20 0.56
MAOA P21397 1/20 0.53
MAPT P10636 2/20 0.53
AR P10275 3/20 0.52
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
TP53 P04637 2/20 0.51
CYP3A4 P08684 2/20 0.51
EDNRA P25101 1/20 0.50
POLH Q9Y253 1/20 0.50
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31485737 0.86 ALDH1A1 (0.59) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL15842695 0.86 CYP2A6 (0.59) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL15306012 0.83 ALDH1A1 (0.49) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL5342730 0.81 MAOA (0.56) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL15842423 0.80 KDM4E (0.53) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL9368338 0.79 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL67224 0.78 ALDH1A1 (1.00) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL11095245 0.77 ALDH1A1 (0.69) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL13191308 0.76 MAPT (0.56) ALDH1A1KDM4EHPGDHSD17B10TDP1
SCHEMBL9725289 0.76 ALDH1A1 (0.45) ALDH1A1KDM4EHPGDHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 US disclosed
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2019-06-27 US disclosed
US-10265316-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUCTICS LIMITED (GB) 2019-04-23 US disclosed
US-20170273981-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2017-09-28 US disclosed
US-20170273981-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2017-09-28 US disclosed
US-20160251340-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2016-09-01 US disclosed
US-20160251340-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS GLAXOSMITHKLINE S.P.A. (IT) 2016-09-01 US disclosed
US-9346790-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2016-05-24 US disclosed
US-9346790-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2016-05-24 US disclosed
EP-2649066-B1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2015-10-21 EP disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 US disclosed
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-10-10 US disclosed
WO-2012076877-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190192516-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 ALDH1A1 1966/4885KDM4E 1460/4885HPGD 734/4885
US-20160251340-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 ALDH1A1 1789/4885KDM4E 958/4885HPGD 834/4885
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 ALDH1A1 1966/4885KDM4E 1460/4885HPGD 734/4885
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 ALDH1A1 1966/4885KDM4E 1460/4885HPGD 734/4885
US-20170273981-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 ALDH1A1 1789/4885KDM4E 958/4885HPGD 834/4885
US-10265316-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNA3, KCND3, KCNN3 ALDH1A1 1789/4885KDM4E 958/4885HPGD 834/4885
US-20130267510-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNA3, KCND3, KCNN3 ALDH1A1 1789/4885KDM4E 958/4885HPGD 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.